Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Libchaber

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
The Journal of Dermatological Treatment|February 24, 2026
On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapiesMaryia Zhdanava, Timothy Fitzgerald, Porpong Boonmak, et al.
Neurology and Therapy|November 16, 2024
Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice ExperimentJeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, et al.
Patient Preference and Adherence|August 12, 2024
Treatment Preferences of Adult Patients with Attention-Deficit/Hyperactivity Disorder - A Discrete Choice ExperimentJeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, et al.
Journal of Child and Adolescent Psychopharmacology|October 7, 2024
Quality of Life and Outcomes Associated with Adverse Effects in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder and Their Parents/CaregiversJeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, et al.
Physical Review Letters|September 26, 2012
Universal protein fluctuations in populations of microorganismsHanna Salman, Naama Brenner, Chih-kuan Tung, et al.
Journal of Medical Economics|April 21, 2026
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United StatesStephen Williams, Sang Cho, Laura Morrison, et al.
Dermatology and Therapy|June 12, 2026
Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice ExperimentApril W Armstrong, Aseel Bin Sawad, Nisha C Hazra, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
The Journal of Dermatological Treatment|February 24, 2026
On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapiesMaryia Zhdanava, Timothy Fitzgerald, Porpong Boonmak, et al.
Neurology and Therapy|November 16, 2024
Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice ExperimentJeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, et al.
Patient Preference and Adherence|August 12, 2024
Treatment Preferences of Adult Patients with Attention-Deficit/Hyperactivity Disorder - A Discrete Choice ExperimentJeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, et al.
Journal of Child and Adolescent Psychopharmacology|October 7, 2024
Quality of Life and Outcomes Associated with Adverse Effects in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder and Their Parents/CaregiversJeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, et al.
Physical Review Letters|September 26, 2012
Universal protein fluctuations in populations of microorganismsHanna Salman, Naama Brenner, Chih-kuan Tung, et al.
Journal of Medical Economics|April 21, 2026
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United StatesStephen Williams, Sang Cho, Laura Morrison, et al.
Dermatology and Therapy|June 12, 2026
Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice ExperimentApril W Armstrong, Aseel Bin Sawad, Nisha C Hazra, et al.
Pageof 7